FDA Calls for Head-to-Head Trials in Revised Draft Guidance on Hepatitis C Drugs

Hepatitis Awareness Without Action Equals Death
May 9, 2016
Multiple sclerosis vs. ALS: Differences in symptoms, causes, and treatment
May 10, 2016
Show all

FDA Calls for Head-to-Head Trials in Revised Draft Guidance on Hepatitis C Drugs

The FDA aims to increase research on comparisons of various direct-acting antiviral medications for hepatitis C.

The US Food and Drug Administration (FDA) on Tuesday released a revised version of its draft guidance on direct-acting antiviral (DAA) Hepatitis C virus (HCV) drugs, which calls on sponsors to conduct head-to-head Phase III studies for drugs in development.

FDA says the draft guidance only applies to drugs with a mechanism that interferes with HCV replication, “through a direct interaction with the HCV genome, polyprotein, or its polyprotein cleavage products,” and does not cover new immune-based drugs or those that work to prevent or reverse outcomes of chronic HCV.

New Revision

Since FDA last revised the guidance in October 2013, there has been a massive shift in the treatment of HCV, brought on by a new generation of cures reaping tens of billions of dollars in sales, including Gilead’s Sovaldi (sofosbuvir) and Harvoni (ledipasvir and sofosbuvir), AbbVie’s Viekra Pak (ombitasvir, paritaprevir, ritonavir and dasabuvir) and Technivie (ombitasvir, paritaprevir and ritonavir) and Merck’s Zepatier (elbasvir and grazoprevir).

Prior to the development of DAA drugs to treat HCV, standard treatment involved a combination of pegylated interferon and ribavirin over the course of 24 or 48 weeks, depending on the specific HCV genotype being treated. However, current generation DAA drugs are able to cure upwards of 90% of patients, without the use of interferon, in as little as 12 weeks.

Due to these vast improvements, FDA says it was necessary to revise its guidance to focus more heavily on interferon-free regimens, provide more detailed recommendations for Phase II and Phase III clinical trials and clarify expectations for trial design for patients with other comorbidities, including co-infection with human immunodeficiency virus-1 (HIV-1) and advanced chronic kidney disease.

Significantly, FDA says it now expects sponsors of new HCV DAAs to conduct at least one head-to-head Phase III trial against an approved comparator.

Read Full Article: FDA Calls for Head-to-Head Trials in Revised Draft Guidance on Hepatitis C Drugs | RAPS


The health and medical information on our website is not intended to take the place of advice or treatment from health care professionals. It is also not intended to substitute for the users’ relationships with their own health care/pharmaceutical providers.

Comments are closed.